Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (288)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Correspondence (3)
  8. Editorial (3)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (785)
  2. Department of Medicine (785)
  3. Hematologic Malignancies, Division of (785)
  4. Lymphoma (785)
  5. Survivorship Research (234)
  6. Population Sciences Research Program (189)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (188)
  3. Paul Hamlin (187)
  4. Steven Horwitz (169)
  5. David Straus (163)
  6. Maria Palomba (143)

More People

Years
  1. 2025 (8)
  2. 2024 (31)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (31)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Elsevier Inc. (31)
  6. Oxford University Press (31)

More Publishers

Results (785)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results
    Meeting Abstract

    Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Eradat, H. A.; Robak, T.; Delgado, J.; Schuh, A.; Pristupa, A. S.; Omyla-Staszewska, J.; Barrlentos, J. C.; Farber, C. M.; Macdonald, D.; Jacob, A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL
    Meeting Abstract

    Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • High body mass index (BMI) in North American elderly diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab (R)-CHOP compensates for negative impact of male gender
    Meeting Abstract

    Zhou, Z.; Rademaker, A. W.; Gordon, L. I.; LaCasce, A. S.; Crosby-Thompson, A.; Vanderplas, A.; Abel, G. A.; Rodriguez, M. A.; Nademanee, A.; Kaminski, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase 2 study of idelalisib monotherapy in previously untreated patients >= 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    Zelenetz, A. D.; Lamanna, N.; Kipps, T. J.; Coutre, S. E.; O'Brien, S.; Aiello, M.; Cho, Y.; Dubowy, R. L.; Flinn, I. W.
    Blood (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors
    Meeting Abstract

    Sharman, J. P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A comprehensive clinical next generation sequencing-based assay can impact hematopathologic diagnosis in a significant subset of patients with hematologic malignancies
    Meeting Abstract

    Pichardo, J. D.; Feldstein, J. T.; Arcila, M.; Batlevi, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.; Tallman, M. S.; Stein, E. M.; Klimek, V. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naive patients ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    O'Brien, S.; Lamanna, N.; Kipps, T. J.; Flinn, I. W.; Zelenetz, A. D.; Burger, J. A.; Holes, L. M.; Cho, Y. J.; Dubowy, R. L.; Coutre, S. E.
    Blood (2014)

    Fulltext@MSK | Save